Monoamine Involvement in the Antidepressant-Like Effect of β-Caryophyllene
| Autor: | Elson Alves Costa, Iziara Ferreira Florentino, Pablinny Moreira Galdino, Fábio Fagundes da Rocha, Daiany Priscilla Bueno da Silva, Dayane Moreira da Silva, James Oluwagbamigbe Fajemiroye, Adriane Ferreira de Brito, Danillo Ramos de Oliveira |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Serotonin Population Pharmacology Motor Activity Open field 03 medical and health sciences 0302 clinical medicine Prazosin Medicine Animals education Polycyclic Sesquiterpenes education.field_of_study Depressive Disorder Major Behavior Animal business.industry Depression General Neuroscience Antagonist Tail suspension test Antidepressive Agents Yohimbine 030104 developmental biology Monoamine neurotransmitter Hindlimb Suspension Antidepressant business Sesquiterpenes 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | CNSneurological disorders drug targets. 17(4) |
| ISSN: | 1996-3181 |
| Popis: | Background: Major depressive disorder is a psychiatric disorder that affects 4.4% of the population worldwide. Although the majority of antidepressant drugs ameliorate depressive symptoms, there is still a need for safer and more effective antidepressant. Objective: Evaluate the antidepressant-like activity of sesquiterpene compound β-caryophyllene (BCP) for the possible contribution of the monoamine and hippocampal levels of brain-derived neurotrophic factor (BDNF). Methods: Male albino Swiss mice were subjected to the forced swimming test after acute treatment and to the tail suspension test after repeated treatment. Hippocampal levels of BDNF were assayed by enzyme-linked immunosorbent assay. Results: The anti-immobility effect of BCP was reverted by pretreatment with an inhibitor of catecholamine synthesis α-methyl-p-tyrosine (100 mg/kg, i.p.), α2-adrenergic antagonist yohimbine (1 mg/kg, i.p.), and β-adrenergic antagonist propranolol (2 mg/kg, i.p.), but not by pretreatment with either α1-adrenergic antagonist prazosin (1 mg/kg, i.p.) or 5-HT1A antagonist NAN-190 (0.5 mg/kg, i.p.), thereby suggesting the involvement of α2 and β-adrenergic receptors, but not of the α1-adrenergic and 5-HT1A serotonergic receptors, in BCP's antidepressive-like activity. Furthermore, BCP increased BDNF levels in the hippocampus after 14 days of treatment. No treatments in this study altered locomotor activity in the open field test. Conclusion: This study provides a new mechanism of BCP-induced antidepressant-like effect mediated by some sub-types of catecholaminergic neurotransmitter system that could be a candidate for clinical tests of new treatments for depressive disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|